Clinical Trial Update: Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating pembrolizumab as maintenance therapy in treated patients with unresectable stage III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Turin, Italy | Conditions: Non Small Cell Lung Cancer Patients | Phase 2 | Status: UNKNOWN